Furthermore, the TCR engineering method is laborious and time consuming, requiring HLA matching of patients and TCR clones and the presentation of tumor-antigen on MHC that is generally down-regulated in tumor cells, restricting its application. The gene discussed is HLA-C; the disease is neoplasm.